XML 16 R5.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Total
Series F Preferred Stock
Series F-4
Series F-3
Series F-2
Stock options
Employee Stock Purchase Plan
Preferred Stock
Preferred Stock
Series F Preferred Stock
Preferred Stock
Series F-3
Preferred Stock
Series F-2
Common Stock
Common Stock
Series F Preferred Stock
Common Stock
Series F-4
Common Stock
Series F-3
Common Stock
Series F-2
Additional Paid in Capital
Additional Paid in Capital
Series F Preferred Stock
Additional Paid in Capital
Series F-4
Additional Paid in Capital
Series F-3
Additional Paid in Capital
Series F-2
Additional Paid in Capital
Stock options
Additional Paid in Capital
Employee Stock Purchase Plan
Accumulated Deficit
Accumulated Other Comprehensive Income
Beginning balance (in shares) at Dec. 31, 2023               24,819       22,761,554                          
Beginning balance at Dec. 31, 2023 $ 15,777             $ 0       $ 228         $ 520,576             $ (505,162) $ 135
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                  
Compensation expense           $ 2,895 $ 50                             $ 2,895 $ 50    
Private placement -issuance of common shares, net of expenses (in shares)                       876,627                          
Private placement -issuance of common shares, net of expenses 6,912                     $ 8                     6,904    
Issuance of common stock with the Employee Stock Purchase Plan (in shares)                       21,140                          
Issuance of common stock with the Employee Stock Purchase Plan 74                               74                
Conversion of shares (in shares)                 (8,010)       1,779,998                        
Conversion of shares   $ 1                     $ 18         $ (17)              
Net income (loss) (11,111)                                             (11,111)  
Unrealized gain (loss) on investments adjustments 8                                               8
Foreign currency translation adjustments 14                                               14
Ending balance (in shares) at Mar. 31, 2024               16,809       25,439,319                          
Ending balance at Mar. 31, 2024 14,620             $ 0       $ 254         530,482             (516,273) 157
Beginning balance (in shares) at Dec. 31, 2023               24,819       22,761,554                          
Beginning balance at Dec. 31, 2023 15,777             $ 0       $ 228         520,576             (505,162) 135
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                  
Net income (loss) (22,988)                                                
Unrealized gain (loss) on investments adjustments (147)                                                
Foreign currency translation adjustments 23                                                
Ending balance (in shares) at Sep. 30, 2024               12,342       28,019,599                          
Ending balance at Sep. 30, 2024 8,571             $ 0       $ 280         536,430             (528,150) 11
Beginning balance (in shares) at Mar. 31, 2024               16,809       25,439,319                          
Beginning balance at Mar. 31, 2024 14,620             $ 0       $ 254         530,482             (516,273) 157
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                  
Compensation expense           3,021 48                             3,021 48    
Prior quarter private placement - expenses (141)                               (141)                
Warrant exercise and conversion - F-4 Preferred to Common (in shares)                           41,666                      
Warrant exercise and conversion - F-4 Preferred to Common     $ 355                               $ 355            
Conversion of shares (in shares)                   (3,010) (1,457) 1,307,706     668,888 441,514                  
Conversion of shares 10     $ 0 $ 0             $ 13     $ 7 $ 4 (3)     $ (7) $ (4)        
Stock option exercise (in shares)                       32,300                          
Stock option exercise 169                     $ 1         168                
Net income (loss) (13,741)                                             (13,741)  
Unrealized gain (loss) on investments adjustments (141)                                               (141)
Foreign currency translation adjustments (8)                                               (8)
Ending balance (in shares) at Jun. 30, 2024               12,342       27,931,393                          
Ending balance at Jun. 30, 2024 4,192             $ 0       $ 279         533,919             (530,014) 8
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                  
Compensation expense           2,092 49                             2,092 49    
Issuance of common stock with the Employee Stock Purchase Plan (in shares)                       50,418                          
Issuance of common stock with the Employee Stock Purchase Plan 175                     $ 1         174                
Stock option exercise (in shares)                       37,788                          
Stock option exercise 196                               196                
Net income (loss) 1,864                                             1,864  
Unrealized gain (loss) on investments adjustments (14)                                               (14)
Foreign currency translation adjustments 17                                               17
Ending balance (in shares) at Sep. 30, 2024               12,342       28,019,599                          
Ending balance at Sep. 30, 2024 8,571             $ 0       $ 280         536,430             (528,150) 11
Beginning balance (in shares) at Dec. 31, 2024               14,192       33,061,002                          
Beginning balance at Dec. 31, 2024 68,746             $ 0       $ 331         599,881             (531,548) 82
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                  
Compensation expense           6,813 50                             6,813 50    
Issuance of common stock with the Employee Stock Purchase Plan (in shares)                       35,513                          
Issuance of common stock with the Employee Stock Purchase Plan 238                               238                
Warrant Exercise - Series F (in shares)                         238,500                        
Warrant Exercise - Series F   2,385                     $ 2         2,383              
Stock option exercise (in shares)                       101,597                          
Stock option exercise 630                     $ 1         629                
Net income (loss) 1,069                                             1,069  
Unrealized gain (loss) on investments adjustments 239                                               239
Foreign currency translation adjustments 60                                               60
Ending balance (in shares) at Mar. 31, 2025               14,192       33,436,612                          
Ending balance at Mar. 31, 2025 80,230             $ 0       $ 334         609,994             (530,479) 381
Beginning balance (in shares) at Dec. 31, 2024               14,192       33,061,002                          
Beginning balance at Dec. 31, 2024 $ 68,746             $ 0       $ 331         599,881             (531,548) 82
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                  
Stock option exercise (in shares) 573,791                                                
Net income (loss) $ 4,596                                                
Unrealized gain (loss) on investments adjustments 592                                                
Foreign currency translation adjustments 201                                                
Ending balance (in shares) at Sep. 30, 2025               14,192       35,308,939                          
Ending balance at Sep. 30, 2025 114,847             $ 0       $ 353         640,571             (526,952) 875
Beginning balance (in shares) at Mar. 31, 2025               14,192       33,436,612                          
Beginning balance at Mar. 31, 2025 80,230             $ 0       $ 334         609,994             (530,479) 381
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                  
Compensation expense           7,159 50                             7,159 50    
Warrant Exercise - Series F (in shares)                         1,377,275                        
Warrant Exercise - Series F   $ 13,773                     $ 14         $ 13,759              
Stock option exercise (in shares)                       142,087                          
Stock option exercise 866                     $ 2         864                
Net income (loss) 2,697                                             2,697  
Unrealized gain (loss) on investments adjustments 57                                               57
Foreign currency translation adjustments 154                                               154
Ending balance (in shares) at Jun. 30, 2025               14,192       34,955,974                          
Ending balance at Jun. 30, 2025 104,986             $ 0       $ 350         631,826             (527,782) 592
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                  
Compensation expense           $ 5,567 $ 81                             $ 5,567 $ 81    
Issuance of common stock with the Employee Stock Purchase Plan (in shares)                       22,858                          
Issuance of common stock with the Employee Stock Purchase Plan 243                               243                
Stock option exercise (in shares)                       330,107                          
Stock option exercise 2,857                     $ 3         2,854                
Net income (loss) 830                                             830  
Unrealized gain (loss) on investments adjustments 296                                               296
Foreign currency translation adjustments (13)                                               (13)
Ending balance (in shares) at Sep. 30, 2025               14,192       35,308,939                          
Ending balance at Sep. 30, 2025 $ 114,847             $ 0       $ 353         $ 640,571             $ (526,952) $ 875